Allena Pharmaceuticals Inc (NASDAQ:ALNA) – Equities research analysts at Jefferies Financial Group lowered their Q3 2018 earnings estimates for shares of Allena Pharmaceuticals in a report released on Monday, August 13th. Jefferies Financial Group analyst M. Andrews now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their prior estimate of ($0.40). Jefferies Financial Group also issued estimates for Allena Pharmaceuticals’ Q4 2018 earnings at ($0.48) EPS, FY2018 earnings at ($1.71) EPS, FY2019 earnings at ($1.95) EPS, FY2020 earnings at ($1.88) EPS and FY2021 earnings at ($1.59) EPS.
Other research analysts have also recently issued research reports about the company. B. Riley upped their price target on Allena Pharmaceuticals from $23.50 to $25.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. LADENBURG THALM/SH SH assumed coverage on Allena Pharmaceuticals in a report on Thursday, August 2nd. They issued a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research cut Allena Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Cowen reaffirmed a “buy” rating on shares of Allena Pharmaceuticals in a report on Wednesday, August 8th. Finally, ValuEngine raised shares of Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $29.14.
Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.02).
A number of large investors have recently made changes to their positions in the business. Partner Fund Management L.P. raised its stake in Allena Pharmaceuticals by 18.8% during the 2nd quarter. Partner Fund Management L.P. now owns 1,739,805 shares of the company’s stock valued at $22,670,000 after purchasing an additional 275,911 shares during the period. BlackRock Inc. raised its stake in Allena Pharmaceuticals by 145.1% during the 2nd quarter. BlackRock Inc. now owns 567,707 shares of the company’s stock valued at $7,397,000 after purchasing an additional 336,053 shares during the period. Sphera Funds Management LTD. raised its stake in Allena Pharmaceuticals by 26.2% during the 1st quarter. Sphera Funds Management LTD. now owns 410,199 shares of the company’s stock valued at $4,520,000 after purchasing an additional 85,199 shares during the period. Millennium Management LLC raised its stake in Allena Pharmaceuticals by 138.2% during the 2nd quarter. Millennium Management LLC now owns 219,351 shares of the company’s stock valued at $2,858,000 after purchasing an additional 127,272 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in Allena Pharmaceuticals during the 4th quarter valued at $499,000. 82.59% of the stock is currently owned by institutional investors.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.